Skip to content

Evaluation of Functional Improvement After Spa Therapy in Fontcaude Center

Evaluation of Functional Improvement After Spa Therapy in Fontcaude Center, for Knee Osteoarthritis

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03289078
Acronym
FONTCAUDE
Enrollment
0
Registered
2017-09-20
Start date
2017-10-31
Completion date
2020-10-31
Last updated
2021-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

Evaluation of functional improvement after spa therapy in Fontcaude center, for knee osteoarthritis Background. Knee osteoarthritis is the first indication of spa therapy in rheumatology. This therapeutic represents a non pharmacological treatment and is recommended by OARSI. In order to obtain agreement for spa therapy, the center Fontcaude, needs to show clinical improvement for patients, as demonstrated in the Thermarthrose study. This center is near Montpellier and could improve patients localised in this area.

Detailed description

Methods: randomised prospective clinical trial of patients with knee osteoarthritis. The spa therapy group received 18 days of therapy over 3 weeks. Patients in the control group received 18 days of therapy over 3 weeks after the 6-month follow-up visit. Follow-up was at 3 and 6 months, by a visit to the examination. The hypothesis of our study is to demonstrate clinical improvement at six months. The main endpoint is the number of patients achieving minimal clinically important improvement (MCII) at 6 months, defi ned as ≥19.9 mm on the visual analogue pain scale and/or ≥9.1 points in a normalised Western Ontario and McMaster Universities osteoarthritis index function score.

Interventions

The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)

Sponsors

FONTCAUDE's Vichy SPA center, Juvignac
CollaboratorUNKNOWN
University Hospital, Montpellier
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patient aged 40 to 75 years with radiologic and gonarthrosis radiologic et painful gonarthrosis, unilateral ou bilateral, whatever is the radiographic stage * Patient presenting a EVA ≥3 with a corresponding radiology at least of 1year * Patient affiliated with a social security system

Exclusion criteria

* Realization of a water cure in the last 6 months * Infiltration of the knee of less than 3 months * Impossibility to sign the informed consent or which for reasons geographical, social or psychological could not be regularly followed, * Person major placed under guardianship or trusteeship, * Private person of freedom by court or administrative order, nobody being the object of a legal protective measure, * Patient already included in an interventional clinical protocol, * Pregnant women * Contraindication in the water cure: * Severe change of the general state or debilitating afflictions * Acute affections and pushed acute(sharp) of the chronic affections * Grave cardiac insufficiency, unstable arterial high blood pressure * Severe renal or hepatic insufficiency * Not healed cutaneous hurts * Contagious or evolutionary diseases * Evolutionary Cancers * Current immunomodulator or immunosupressor Treatment, waves of inflammation.

Design outcomes

Primary

MeasureTime frameDescription
Achievement of minimal clinically important improvement (MCII) at 6 months30 monthsThe main endpoint is the number of patients achieving minimal clinically important improvement (MCII) at 6 months, defined as ≥19.9 mm on the visual analogue pain scale and/or ≥9.1 points in a normalised Western Ontario and McMaster Universities osteoart

Secondary

MeasureTime frameDescription
Achievement of minimal clinically important improvement (MCII) at 3 months30 monthsThe second outcome measure is the number of patients achieving minimal clinically important improvement (MCII) at 3 months, defi ned as ≥19.9 mm on the visual analogue pain scale and/or ≥9.1 points in a normalised Western Ontario and McMaster Universities osteoarthritis index function score, and also the safety.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026